Full Library
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)
Resource type
Journal Article
Authors/contributors
- Chong, Pearlie P. (Author)
- Teiber, Dagny (Author)
- Prokesch, Bonnie C. (Author)
- Arasaratnam, Reuben J. (Author)
- Peltz, Matthias (Author)
- Drazner, Mark H. (Author)
- Garg, Sonia (Author)
Title
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)
Abstract
Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.
Publication
Transplant Infectious Disease
Date
2018
Volume
20
Issue
5
Pages
e12965
Accessed
12/13/18, 6:11 PM
ISSN
1399-3062
Language
en
Library Catalog
Wiley Online Library
License
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Citation
Chong, P. P., Teiber, D., Prokesch, B. C., Arasaratnam, R. J., Peltz, M., Drazner, M. H., & Garg, S. (2018). Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Transplant Infectious Disease, 20(5), e12965. https://doi.org/10.1111/tid.12965
ORGANISMS
Link to this record